RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
RBC Capital analyst Luca Issi maintains $Editas Medicine(EDIT.US)$ with a hold rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 22.6% and a
Editas Medicine (EDIT) Receives a Hold From RBC Capital
Jones Trading Initiates Coverage On Editas Medicine With Buy Rating, Announces Price Target of $13
JonesTrading Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $13
JonesTrading analyst Soumit Roy initiates coverage on $Editas Medicine(EDIT.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 23.5%
Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough
We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Editas Medicine Hold Rating With Revised Price Target Amidst Mixed Financial Signals
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline
Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
Earnings Call: Editas Medicine Optimistic Despite HHS Decision
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Barclays Remains a Hold on Editas Medicine (EDIT)
Buy Rating on Editas Medicine as R&D Progress Signals Market Potential for Sickle Cell and Thalassemia Treatments
Editas Medicine Raised to Buy From Neutral by B of A Securities
Editas Medicine Price Target Raised to $15.00/Share From $13.00 by B of A Securities